Prescription of Testosterone-Lowering Medications for Sex Offender Treatment in German Forensic-Psychiatric Institutions
Authors:
- 1 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 10 (2) , 570-578
Abstract
Different clinical guidelines suggest using testosterone-lowering medications (TLM) in sex offender treatment in addition to psychotherapy. Within Germany, there are two officially approved agents. So far, no current data exist about the routine use of TLM in a clinical context. The present observational study evaluates the frequency of the prescription of TLM and other medications in sex offender treatment in German forensic-psychiatric institutions. Experts are asked about the observed effects and side effects of TLM. The heads of all 69 German forensic-psychiatric hospitals and outpatient clinics were asked to fill out a questionnaire assessing offender characteristics and treatment methods in use. Main outcome measures were the number of patients being treated with TLM and other pharmacological agents for reducing sexual drive. Further effects and side effects of the agents were evaluated. Thirty-two participating institutions reported on 3,963 patients, 611 of them being sex offenders (15.4%). Most sex offenders had been convicted for child sexual abuse (39.8%) or a sexual assault/rape (37.6%). Almost all sex offenders were treated psychotherapeutically and 37% were receiving an additional pharmacological treatment. Of all the sex offenders, 15.7% were treated with TLM; 10.6% were treated with a gonadotropin-releasing hormone agonist; and 5.1% were treated with cyproterone acetate. Of these, 26.0-75.4% showed improvements in such outcomes as reduction of frequency and/or intensity of sexual thoughts. The remaining 21.3% of sex offenders who received a pharmacological agent were treated with selective serotonin reuptake inhibitors (11.5%) or antipsychotic medications (9.8%). TLM are a frequently used addition to psychotherapy in sex offenders. In light of the lack of controlled clinical trials and the many side effects, benefits and risks should always be thoroughly assessed.Keywords
This publication has 42 references indexed in Scilit:
- The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of paraphiliasThe World Journal of Biological Psychiatry, 2010
- Antiandrogene Therapie und Lockerungen bei Sexualstraftätern im Maßregelvollzug BerlinPsychiatrische Praxis, 2009
- Side Effects of Pharmacotherapy on Bone with Long-Acting Gonadorelin Agonist Triptorelin for ParaphiliaThe Journal of Sexual Medicine, 2008
- The prevalence of diabetes among sexual and violent offenders and its co‐occurrence with cognitive impairment, mania, psychotic symptoms and aggressive behaviorInternational Journal of Prisoner Health, 2008
- Selektive Serotoninwiederaufnahmehemmer (SSRI) in der Behandlung von ParaphilienFortschritte der Neurologie · Psychiatrie, 2006
- Pharmacotherapy of Paraphilias With Long-Acting Agonists of Luteinizing Hormone–Releasing HormoneThe Journal of Clinical Psychiatry, 2003
- Antihormonal treatment of paraphilic patients in German forensic psychiatric clinicsEuropean Psychiatry, 2002
- Physical and Chemical Castration of Sex OffendersJournal of Offender Rehabilitation, 1997
- Antiandrogentherapie der pathologisch gesteigerten und abartigen Sexualität des MannesJournal of Molecular Medicine, 1967
- HORMONE TREATMENT OF THE SEXUAL OFFENDERThe Lancet, 1949